



Signal Genetics Announces Licensing Agreement of Novel Microarray Diagnostic for the Predictive Determination of Multiple Myeloma Staging & Prognosis with University of Arkansas Medical Sciences

New York, NY, September 7, 2010 – Signal Genetics, a privately held predictive genetic testing company directed toward cancer patients, today announced that the company has acquired an exclusive license to technologies developed at the University of Arkansas Medical Sciences.

These technologies based in microarray genomic profiling, with over 10 years of study and testing on over 6,000 patients have proven their ability to predict the stage, calculate the odds of relapse, and lead physicians to the optimal treatment regimen for those suffering from myeloma. This specific means of predictive genetic testing was published in the May 2006 issue of the journal *Blood* in which specific genetic markers were correlated to the specific disease stages one suffering from myeloma could expect to see in their lifetime.

“This licensure allows Signal Genetics to provide industry leading cancer testing and diagnostic services to myeloma patients. These diagnostic services are in place to help steer cancer patients through this difficult time in their health care management and to bring about a more clear path to their future treatment options. Within the next year Signal Genetics plans to expand their diagnostic testing options to serve the broader cancer patient community, with diagnostic testing capabilities for many of the higher incident cancers affecting the worlds population,” stated Joe Hernandez.

About Signal Genetics.

Signal Genetics is a privately held predictive genetic testing company directed towards cancer patients. The goal of Signal Genetics is to supply cancer patients with their correlated predictive outcome of disease stage, odds of relapse, and guide physicans to the optimal treatment regimine based on their specific genetic expression profile. Additional information available at www.signalgenetics.com

Contact Info:

Signal Genetics Media Relations

1-212-486-0040

info@signalgenetics.com

www.signalgenetics.com